138 related articles for article (PubMed ID: 32437025)
1. Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Itou M; Fujita T; Inoue K; Uchida N; Takagaki T; Ishii D; Kakuyama H
J Clin Pharmacol; 2020 Oct; 60(10):1397-1403. PubMed ID: 32437025
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ranirestat for the treatment of diabetic neuropathy.
Giannoukakis N
Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Giannoukakis N
Curr Opin Investig Drugs; 2006 Oct; 7(10):916-23. PubMed ID: 17086937
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Polydefkis M; Arezzo J; Nash M; Bril V; Shaibani A; Gordon RJ; Bradshaw KL; Junor RW;
J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Matsumoto T; Ono Y; Kuromiya A; Toyosawa K; Ueda Y; Bril V
J Pharmacol Sci; 2008 Jul; 107(3):340-8. PubMed ID: 18612195
[TBL] [Abstract][Full Text] [Related]
10. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
Nafziger AN; Arscott KA; Cochrane K; Skobieranda F; Burt DA; Fossler MJ
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):639-650. PubMed ID: 31697049
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
[TBL] [Abstract][Full Text] [Related]
12. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Bril V; Hirose T; Tomioka S; Buchanan R;
Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
[TBL] [Abstract][Full Text] [Related]
13. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Giannoukakis N
Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Bril V; Buchanan RA
Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM; Venkatakrishnan K; Ramanathan RK; Sarantopoulos J; Mulkerin D; Shibata SI; Hamilton A; Dowlati A; Mani S; Rudek MA; Takimoto CH; Neuwirth R; Esseltine DL; Ivy P
Clin Cancer Res; 2012 May; 18(10):2954-63. PubMed ID: 22394984
[TBL] [Abstract][Full Text] [Related]
17. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
18. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
19. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.
Kang Y; Li Y; Xu F; Zhang J; Wang K; Chen Y; Wu J; Guo B; Yu J; Zhang Y
Clin Ther; 2019 Mar; 41(3):505-517.e0. PubMed ID: 30819510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
